a public good project by the
Synthesis
Company
of California

© 2026

Luke Hughes‐Davies | doi.page

0 works0 citations0 h-index

Luke Hughes‐Davies

Cambridge University Hospitals NHS Foundation Trust(GB)

Publications by Year

Research Areas

Breast Cancer Treatment Studies, BRCA gene mutations in cancer, HER2/EGFR in Cancer Research, Cancer Genomics and Diagnostics, Cancer Treatment and Pharmacology

Most-Cited Works

→ DNA methyltransferase Dnmt1 associates with histone deacetylase activity(2000)970 cited
→ The Tudor domain ‘Royal Family’: Tudor, plant Agenet, Chromo, PWWP and MBT domains(2003)481 cited
→ EMSY Links the BRCA2 Pathway to Sporadic Breast and Ovarian Cancer(2003)420 cited
→ 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial(2019)278 cited
→ Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others(2016)213 cited
→ Transcriptional activation functions in BRCA2(1997)204 cited
→ A Functionally Significant Cross-talk between Androgen Receptor and ErbB2 Pathways in Estrogen Receptor Negative Breast Cancer

(2008)

159 cited

→ Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial(2015)133 cited

→ Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial(2013)119 cited

→ The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation(2018)96 cited